Abstract:Cyclophilin J (CyPJ), also called peptidylprolyl isomerase like 3, has been identified as a novel member of the cyclophilin family. Our previous research has resolved the three-dimensional structure of CyPJ and demonstrated the peptidylprolyl cis-trans isomerase (PPIase) activity of CyPJ, which can be inhibited by the common immunosuppressive drug cyclosporine A (CsA). Importantly, CyPJ is upregulated in hepatocellular carcinoma (HCC) and promotes tumor growth; CyPJ inhibition by CsA-or siRNA-based knockdown results in a remarkable suppression of HCC. These findings suggest that CyPJ may be a potential therapeutic target for HCC, and discovery of relevant inhibitors may facilitate development of a novel CyPJ-based targeting therapy. However, apart from the common inhibitor CsA, CyPJ has yet to be investigated as a target for cancer therapy. Here, we report structure-based identification of novel small molecule non-peptidic CyPJ inhibitors and their potential as antitumor lead compounds. Based on computer-aided virtual screening, in silico, and subsequently surface plasmon resonance analysis, 19 potential inhibitors of CyPJ were identified and selected for further evaluation of PPIase CyPJ inhibition in vitro. Thirteen out of 19 compounds exhibited notable inhibition against PPIase activity. Among them, the compound ZX-J-19, with a quinoxaline nucleus, showed potential for tumor inhibition; thus, we selected it for further structure-activity optimization. A total of 22 chemical derivatives with 2,3-substituted quinoxaline-6-amine modifications were designed and successfully synthesized. At least 2 out of the 22 derivatives, such as ZX-J-19j and ZX-J-19l, demonstrated remarkable inhibition of tumor cell growth, comparable to CsA but much stronger than 5-fluorouracil. These results indicate that these two small molecules represent novel potential lead compounds for CyPJ-based antitumor drug development.

Novel Class of Cyclophosphamide Prodrug: Cyclophosphamide Spiropiperaziniums (Cpsp)

Novel Class of Cyclophosphamide Prodrug: Cyclophosphamide Spiropiperaziniums (CPSP).

A Novel Class of Cyclophosphamide Prodrug: Structure-Activity Relationships of Cyclophosphamide Piperaziniums

A Novel Sulfonamide Agent, MPSP-001, Exhibits Potent Activity Against Human Cancer Cells in Vitro Through Disruption of Microtubule

Synthesis and anticancer activity of novel C6-piperazine substituted purine steroid–nucleosides analogues

Novel Spiropyrazolone Antitumor Scaffold with Potent Activity: Design, Synthesis and Structure–activity Relationship

Structurally Novel PI3Kδ/γ Dual Inhibitors Characterized by a Seven-Membered Spirocyclic Spacer: the SARs Investigation and PK Evaluation.

Discovery of Novel Polycyclic Spiro-Fused Carbocyclicoxindole-Based Anticancer Agents

Design, Syntheses, and Characterization of Piperazine Based Chemokine Receptor CCR5 Antagonists As Anti Prostate Cancer Agents.

Synthesis of a novel class of cyclophosphamide bis-spiropiperazinium salts

Modification of the Alkylating Agent Chlorambucil with Spiropiperazinium Salts

Synthesis and Biological Evaluation of Novel C6-cyclo Secondary Amine Substituted Purine Steroid-Nucleosides Analogues.

Structure-Activity Relationship Study of New Carbazole Sulfonamide Derivatives as Anticancer Agents with Dual-target Mechanism

Synthesis Of Diaryl Ether Substituted Piperazine Derivatives And Their Cytotoxic Activities

Design, Synthesis, and Activity Evaluation of Novel Acyclic Nucleosides as Potential Anticancer Agents <i>In Vitro</i> and <i>In Vivo</i>

Cyclophilin J PPIase Inhibitors Derived from 2,3-Quinoxaline-6 Amine Exhibit Antitumor Activity

Synthesis and Antitumor Activities of 5-Carbohydrate Modified Cyclophosphamide Derivates

Structure-Based Drug Design and Identification of H2O-Soluble and Low Toxic Hexacyclic Camptothecin Derivatives with Improved Efficacy in Cancer and Lethal Inflammation Models in Vivo

Design, Synthesis and In‐Silico Studies of Piperidine‐Dihydropyridine Hybrids as Anticancer Agents

Design, Synthesis, and Activity Evaluation of Novel Acyclic Nucleosides as Potential Anticancer Agents In Vitro and In Vivo

New ferrocene cyclopalladated compounds: synthesis, X-ray single crystal structure and in vitro anticancer activity study